(WVE) Wave Life Sciences - Ratings and Ratios
Genetic, Therapy, DNA, RNA
WVE EPS (Earnings per Share)
WVE Revenue
Description: WVE Wave Life Sciences
Wave Life Sciences Ltd (NASDAQ:WVE) is a pharmaceutical company based in Singapore, operating in the biotechnology sector. As a common stock, WVE is listed on the NASDAQ exchange.
The companys market capitalization stands at approximately $1.373 billion USD, indicating a significant presence in the market. However, the P/E ratio is reported as 0.00, suggesting that the company is currently unprofitable, as is common in the pharmaceutical industry where R&D investments are substantial. The Return on Equity (RoE) is -78.45%, further indicating significant losses relative to shareholder equity.
Key economic drivers for Wave Life Sciences include the success of its pipeline drugs, particularly those in clinical trials, and the overall demand for treatments in the therapeutic areas it targets. The companys financial health, including cash burn rate and runway, will be crucial in determining its ability to bring products to market. Investors should monitor upcoming clinical trial results, regulatory approvals, and partnerships or collaborations that could impact the companys financials and stock performance.
To evaluate the stocks potential, investors should consider KPIs such as cash reserves, R&D expenses as a percentage of revenue, and the progress of key drug candidates through the development pipeline. The companys ability to secure funding, either through equity, debt, or partnerships, will be vital for advancing its drug pipeline and achieving profitability.
Given the negative beta of -0.956, WVEs stock price movements tend to move inversely to the broader market, suggesting it could be used as a hedge in a diversified portfolio. However, this also indicates potential volatility, and investors should be cautious. Monitoring the companys announcements, clinical trial results, and industry trends will be essential for making informed investment decisions.
WVE Stock Overview
| Market Cap in USD | 1,274m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception | 2015-11-11 |
WVE Stock Ratings
| Growth Rating | 22.0% |
| Fundamental | 28.6% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 0.47% |
| Analyst Rating | 4.62 of 5 |
WVE Dividends
Currently no dividends paidWVE Growth Ratios
| Growth Correlation 3m | 44.5% |
| Growth Correlation 12m | -52.9% |
| Growth Correlation 5y | 21.8% |
| CAGR 5y | 23.40% |
| CAGR/Max DD 3y | 0.35 |
| CAGR/Mean DD 3y | 0.81 |
| Sharpe Ratio 12m | -0.40 |
| Alpha | 0.18 |
| Beta | 0.126 |
| Volatility | 79.16% |
| Current Volume | 1202.7k |
| Average Volume 20d | 1524.3k |
| Stop Loss | 6.3 (-7.4%) |
| Signal | -1.06 |
Piotroski VR‑10 (Strict, 0-10) 1.5
| Net Income (-129.9m TTM) > 0 and > 6% of Revenue (6% = 5.64m TTM) |
| FCFTA -0.60 (>2.0%) and ΔFCFTA -50.38pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 144.9% (prev -0.95%; Δ 145.9pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.79 (>3.0%) and CFO -199.2m <= Net Income -129.9m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 2.56 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (164.0m) change vs 12m ago 26.60% (target <= -2.0% for YES) |
| Gross Margin 97.71% (prev 57.45%; Δ 40.25pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 40.74% (prev 52.92%; Δ -12.17pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| error: Interest Coverage Ratio cannot be calculated (needs EBITDA TTM and Interest Expense TTM) |
Altman Z'' -16.68
| (A) 0.54 = (Total Current Assets 223.6m - Total Current Liabilities 87.4m) / Total Assets 252.4m |
| (B) -4.83 = Retained Earnings (Balance) -1.22b / Total Assets 252.4m |
| warn (B) unusual magnitude: -4.83 — check mapping/units |
| (C) -0.62 = EBIT TTM -143.5m / Avg Total Assets 230.6m |
| (D) -0.27 = Book Value of Equity -28.3m / Total Liabilities 105.2m |
| Total Rating: -16.68 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 28.57
| 1. Piotroski 1.50pt = -3.50 |
| 2. FCF Yield -13.93% = -5.0 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.18 = 2.48 |
| 5. Debt/Ebitda -0.19 = -2.50 |
| 6. ROIC - WACC (= -93.21)% = -12.50 |
| 7. RoE -77.53% = -2.50 |
| 8. Rev. Trend 12.77% = 0.96 |
| 9. EPS Trend 22.54% = 1.13 |
What is the price of WVE shares?
Over the past week, the price has changed by -7.98%, over one month by -30.18%, over three months by +3.19% and over the past year by +19.09%.
Is Wave Life Sciences a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of WVE is around 6.35 USD . This means that WVE is currently overvalued and has a potential downside of -6.62%.
Is WVE a buy, sell or hold?
- Strong Buy: 9
- Buy: 3
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the WVE price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 20 | 194.1% |
| Analysts Target Price | 20 | 194.1% |
| ValueRay Target Price | 7 | 2.4% |
Last update: 2025-09-05 05:08
WVE Fundamental Data Overview
CCE Cash And Equivalents = 208.5m USD (Cash And Short Term Investments, last quarter)
P/S = 13.559
P/B = 9.1466
Beta = -0.956
Revenue TTM = 93.9m USD
EBIT TTM = -143.5m USD
EBITDA TTM = -134.8m USD
Long Term Debt = 17.8m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 8.14m USD (from shortTermDebt, last quarter)
Debt = 25.9m USD (Calculated: Short Term 8.14m + Long Term 17.8m)
Net Debt = -186.8m USD (from netDebt column, last quarter)
Enterprise Value = 1.09b USD (1.27b + Debt 25.9m - CCE 208.5m)
Interest Coverage Ratio = unknown (Ebit TTM -143.5m / Interest Expense TTM 0.0)
FCF Yield = -13.93% (FCF TTM -152.0m / Enterprise Value 1.09b)
FCF Margin = -161.8% (FCF TTM -152.0m / Revenue TTM 93.9m)
Net Margin = -138.2% (Net Income TTM -129.9m / Revenue TTM 93.9m)
Gross Margin = 97.71% ((Revenue TTM 93.9m - Cost of Revenue TTM 2.16m) / Revenue TTM)
Tobins Q-Ratio = -38.51 (set to none) (Enterprise Value 1.09b / Book Value Of Equity -28.3m)
Interest Expense / Debt = 11.10% (Interest Expense 2.88m / Debt 25.9m)
Taxrate = 21.0% (US default)
NOPAT = -143.5m (EBIT -143.5m, no tax applied on loss)
Current Ratio = 2.56 (Total Current Assets 223.6m / Total Current Liabilities 87.4m)
Debt / Equity = 0.18 (Debt 25.9m / last Quarter total Stockholder Equity 147.1m)
Debt / EBITDA = -0.19 (Net Debt -186.8m / EBITDA -134.8m)
Debt / FCF = -0.17 (Debt 25.9m / FCF TTM -152.0m)
Total Stockholder Equity = 167.5m (last 4 quarters mean)
RoA = -51.46% (Net Income -129.9m, Total Assets 252.4m )
RoE = -77.53% (Net Income TTM -129.9m / Total Stockholder Equity 167.5m)
RoCE = -77.43% (Ebit -143.5m / (Equity 167.5m + L.T.Debt 17.8m))
RoIC = -86.68% (NOPAT -143.5m / Invested Capital 165.6m)
WACC = 6.53% (E(1.27b)/V(1.30b) * Re(6.48%)) + (D(25.9m)/V(1.30b) * Rd(11.10%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 93.94 | Cagr: 5.20%
Discount Rate = 6.48% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
Fair Price DCF = unknown (Cash Flow -152.0m)
EPS Correlation: 22.54 | EPS CAGR: 38.47% | SUE: -0.23 | # QB: 0
Revenue Correlation: 12.77 | Revenue CAGR: 246.6% | SUE: -0.06 | # QB: 0
Additional Sources for WVE Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle